References
- Storz U. Kontermann R, Duebel S. IP Issues in the Therapeutic Antibody Industry. Antibody Engineering 2010; 2:Springer 517 - 581
- Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245 - 255; PMID: 19501012; http://dx.doi.org/10.1016/j.cbpa.2009.04.627
- Storz U. Intellectual property protection: strategies for antibody inventions. MAbs 2011; 3:310 - 317; PMID: 21494091; http://dx.doi.org/10.4161/mabs.3.3.15530
- CV 03-2567 (Cal CD Jan 14, 2004; February 18, 2004; Mar 15, 2004; April 29, 2004). US Supreme Court, Case No. 05-608 1/9/07
- Centocor vs. Genentech and City of Hope, Central District of California, No. 08-CV-03573 MRP
- Glaxo Group Limited et al. vs. Genentech, Inc., et al. 3:10-cv-00675 Northern District of California
- HGS Inc., vs. Genentech, Inc., 11-cv-082-LPS, District of Delaware and HGS Inc., vs. Genentech, Inc., 11-cv-156-LPS, District of Delaware
- HGS Inc., vs. Genentech, Inc.; 11-cv-382-LPS, District of Delaware
- Genentech, Inc., et al. vs. Glaxo Group Limited, et al. CV11-03065 SVW (Central District of California)